Motixafortide: evidence, FDA status and research

It is an injection that frees stem cells into the blood so they can be collected before a transplant for myeloma. A trial of 122 patients showed it worked far better than the usual drug alone.

Sold for

Motixafortide is a hospital drug with no consumer market; it is discussed as a stronger alternative to plerixafor for harvesting stem cells before a myeloma transplant.

Studies say

A 122-patient placebo-controlled trial showed 92.5 percent versus 26 percent of patients reaching the stem cell target in up to two collections, which is enough for an A for this single approved use.

Why grade A. Approval rests on GENESIS, a randomized, double-blind, placebo-controlled phase 3 trial in 122 patients with multiple myeloma in which motixafortide plus filgrastim mobilized the target stem cell dose in far more patients than filgrastim alone. One trial of moderate size supports a narrow indication; the FDA accepted it because the endpoint is objective and the effect was large. Uses in sickle cell disease and solid tumors are in early trials only. ¹²

FDA. Approved. Motixafortide (Aphexda) was approved in September 2023 for use with filgrastim to mobilize hematopoietic stem cells for collection and autologous transplantation in patients with multiple myeloma. It has no other approved indication as of the 2026 label revision. ²

Written from 2 cited sources. Fact-checked 2026-10-27: 14 claims checked, 4 corrected. Last refreshed 2026-10-27. Not physician reviewed.

What this means for you

What people take it for: Collecting stem cells before a transplant
Can a US doctor prescribe it?: Yes, FDA approved for collecting stem cells in people with multiple myeloma.
Properly tested in people?: Yes, in a controlled trial of 122 patients.

Evidence checklist

Randomised controlled trial GENESIS, double-blind placebo-controlledyes
Human study over 100 people GENESIS, 122 patientsyes
More than one research group One pivotal trial from the sponsorno
Clinical outcomes, not surrogate markers Stem cell collection target reachedyes
Human safety data beyond case reports Injection reactions, anaphylaxis documentedyes

Drawn from the cited studies below. A dash means the sources give no information.

What it is

Motixafortide is a lab-made ring-shaped peptide with 14 amino acids. BioLineRx developed it. It blocks CXCR4, the receptor that anchors blood-forming stem cells in the bone marrow. Blocking it frees the cells into the bloodstream. Doctors then collect them by apheresis, a procedure that filters cells from circulating blood. After high-dose chemotherapy for multiple myeloma, the cells are put back. ¹²

The FDA approved it in 2023 as Aphexda. Ayrmid Pharma now issues the label, and Gamida Cell is the US distributor. It is used with filgrastim (G-CSF), the standard mobilizing agent. Patients get it by injection under the skin before apheresis. A second dose is allowed before a third session. Patients first get premedication to limit reactions. ²

How it works

Stem cells stay in the marrow because of a chemokine called CXCL12. Marrow stromal cells make it, and it binds CXCR4 on the stem cell surface. Motixafortide is a long-lasting CXCR4 antagonist with a strong grip. When it occupies the receptor, the cells lose their tether. Over the next day they spill into the blood. Filgrastim helps by expanding the stem cell pool and loosening the marrow. The older drug plerixafor works on the same receptor. It binds more weakly and for a shorter time. ¹

What human research shows

GENESIS randomized 122 patients with multiple myeloma who were preparing for autologous transplant. They got motixafortide or placebo, both with filgrastim. The main measure was collecting at least six million CD34-positive stem cells per kilogram in up to two apheresis sessions. In the motixafortide group, 92.5 percent met it. In the placebo group, 26.2 percent did. In a single session, 88.8 percent of the motixafortide group reached the target. On placebo, 9.5 percent did. After transplant, the new cells took hold quickly and lasted in both arms. ¹

The trial also found that motixafortide pulled out more primitive stem cells. The authors suggested this may matter for graft quality over the long term. But clinical outcomes did not differ during the trial's follow-up. ¹

Study	Model	Finding
GENESIS (Crees 2023)	Humans, n=122 with multiple myeloma, randomized double-blind placebo-controlled phase 3	92.5 percent versus 26.2 percent reached the stem cell collection target in up to two apheresis sessions; engraftment was durable. ¹
Aphexda prescribing information (2026)	FDA label	Approved with filgrastim for stem cell mobilization in multiple myeloma; injection-site and systemic reactions are the main safety concerns. ²

Safety

Injection-site reactions (pain, redness, itching) occurred in 73 percent of patients in GENESIS. They were severe in 9 percent. That is why the label calls for antihistamine and pain-relief premedication. A minority had whole-body reactions such as flushing, itching and hives. Anaphylactic shock was reported. Other common effects were back pain, nausea and low blood pressure. ¹²

The drug moves cells out of the marrow. So the label warns that it may mobilize leukemic cells. It should not be used in leukemia. Tumor cells may enter the collected product, with unknown effect. White cell counts rise. The drug can also harm a developing fetus. Data in patients with kidney impairment are limited. Patients get only one or two doses, so long-term exposure data do not apply. ²

Questions for your clinician

Is a stem cell mobilizer needed in my transplant plan, and which one?
How are the injection-site reactions prevented and treated?
Is there any risk of mobilizing cancer cells in my case?

Questions people ask

What is motixafortide used for?

To release stem cells from the bone marrow into the blood. Doctors can then collect them before an autologous transplant in multiple myeloma. It is given with filgrastim. ²

How does it compare with plerixafor?

Both block CXCR4. Motixafortide binds the receptor longer and more tightly. GENESIS compared it with placebo plus filgrastim. It did not compare it with plerixafor directly, so there is no head-to-head trial. ¹

Which reactions follow dosing?

Injection-site reactions in about three quarters of patients, severe in 9 percent. A minority also had flushing, hives, nausea and low blood pressure. Premedication is part of the label. ¹²

Is motixafortide sold as a peptide online?

It is a prescription drug given once or twice in a hospital before stem cell collection. There is no legitimate consumer supply. It has no use outside transplantation. ²

Citations

Crees 2023, Nature Medicine: Motixafortide and G-CSF for stem cell mobilization in multiple myeloma (GENESIS) doi.org
FDA 2026: Aphexda (motixafortide) prescribing information accessdata.fda.gov